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Background: Mesalamine is the ﬁrst-line drug for the treatment
of ulcerative colitis (UC). We directly compared the efﬁcacy and
safety of two mesalamine formulations for the induction of remis-
sion in patients with UC.
Methods: In a multicenter, double-blind, randomized study, 229
patients with mild-to-moderate active UC were assigned to 4
groups: 66 and 65 received a pH-dependent release formulation of
2.4 g/day (pH-2.4 g) or 3.6 g/day (pH-3.6 g), respectively; 65
received a time-dependent release formulation of 2.25 g/day (Time-
2.25 g), and 33 received placebo (Placebo). The drugs were admin-
istered three times daily for eight weeks. The primary endpoint was
a decrease in the UC disease activity index (UC-DAI).
Results: In the full analysis set (n ¼ 225) the decrease in UC-
DAI in each group was 1.5 in pH-2.4 g, 2.9 in pH-3.6 g, 1.3 in
Time-2.25 g and 0.3 in Placebo, respectively. These results dem-
onstrate the superiority of pH-3.6 g over Time-2.25 g (P ¼ 0.003)
and the noninferiority of pH-2.4 g to Time-2.25 g. Among the
patients with proctitis-type UC, a signiﬁcant decrease in UC-DAI
was observed in pH-2.4 g and pH-3.6 g as compared to Placebo,
but not in Time-2.25 g. No differences were observed in the
safety proﬁles.
Conclusions: Higher dose of the pH-dependent release formula-
tion was more effective for induction of remission in patients
with mild-to-moderate active UC. Additionally, the pH-dependent
release formulation was preferable to the time-dependent release
formulation for patients with proctitis-type UC (UMIN Clinical
Trials Registry, no. C000000288).
(Inﬂamm Bowel Dis 2010;16:1567–1574)
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O
ral mesalamine formulations are widely used for the
treatment of mild-to-moderate active ulcerative colitis
(UC) because they have shown excellent efﬁcacy and
safety, especially with long-term use.
1–3
Mesalamine is absorbed in the upper gastrointestinal
tract;
3–5 whereas, it exerts antiinﬂammatory activity
directly on the inﬂamed mucosa in colon and rectum.
Thus, many types of release-controlled oral formulations of
mesalamine have been developed to enhance its effect.
The most widely-used formulation of mesalamine,
the pH-dependent release formulation coated with Eudra-
git-S (Asacol), has been designed so that the coating ﬁlm
dissolves at a pH of 7 or higher.
3,6,7 The release of mesal-
amine starts in the terminal ileum due to its coating. The
time-dependent release formulation of mesalamine coated
with ethyl cellulose (Pentasa), on the other hand, gradually
releasing mesalamine in the stomach.
3,7 Both formulations
are designed to increase drug delivery to the inﬂamed areas
of the colon and rectum as compared with the unmodiﬁed
formulation. Since there have been no double-blind,
randomized studies comparing the therapeutic efﬁcacy of
these formulations, physicians select these drugs with little
guidance as to their proper use. Therefore, we conducted a
double-blind, randomized trial in patients with active
UC comparing the two formulations in terms of their efﬁ-
cacy and safety (UMIN Clinical Trials Registry, no.
C000000288).
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Patient Selection
We conducted the study on patients with mild-to-
moderate active UC on the basis of two inclusion criteria:
1) outpatients who were 16–64 years of age at the time of
informed consent, and 2) patients who had mild-to-moder-
ate active UC deﬁned by UC-DAI of 3–8 and a bloody
stool score of 1 or greater. The UC-DAI was originally
developed by Sutherland et al.
8
The patients were excluded according to the follow-
ing criteria: 1) severe UC, chronic continuous type UC or
acute fulminating type UC; 2) oral mesalamine more than
2.25 g daily, oral salazosulfapyridine more than 4.5 g daily,
mesalamine enemas, salazosulfapyridine suppositories, cor-
ticosteroids (oral preparations, enemas, suppositories, injec-
tions and/or remedies for hemorrhoidal diseases) and/or
cytapheresis within 14 days before the start of the investi-
gational drug; 3) immunosuppressants within 90 days
before the start of the investigational drug; 4) any other
investigational drug within six months before informed
consent; 5) a history of hypersensitivity to mesalamine or
salicylate drugs, severe cardiac disease, severe pulmonary
disease and/or severe hematological diseases; 6) severe
hepatopathy, severe nephropathy and/or malignant tumors;
and 7) pregnant or lactating.
Ethical Considerations
This study was conducted according to the principles
of the Declaration of Helsinki after obtaining approvals
from the Institutional Review Board at each of the partici-
pating medical centers. Written informed consent was
obtained from all participants.
Study Drugs
The pH-dependent release mesalamine formulation
used in this study is a tablet coated with Eudragit-S (Asa-
col 400 mg tablet, Tillotts Pharma AG, Ziefen, Switzer-
land, supplied by ZERIA Pharmaceutical, Tokyo, Japan).
The time-dependent release mesalamine formulation used
in this study is a tablet coated with ethyl cellulose (Pentasa
250 mg tablet, Nisshin Kyorin Pharmaceutical, Japan). This
study was conducted using a double-dummy method.
Study Design
This double-blind, randomized, controlled study was
conducted at 53 centers in Japan. Treatment assignments
were balanced according to the inﬂamed areas (proctitis-
type or others) and the severity of the disease (range of
UC-DAI at initial assessment: 3–5 or 6–8) with the use of
a biased-coin minimization algorithm. Balance within each
medical center was also taken into consideration. A person
independent from the study was in charge of the random
allocation. Seven patients were assigned as a block as
follows: 2 to a group given the pH-dependent release for-
mulation at 2.4 g/day (pH-2.4 g), 2 to a group given the
pH-dependent release formulation at 3.6 g/day (pH-3.6 g),
2 to a group given the time-dependent release formulation
at 2.25 g/day (Time-2.25 g), and 1 to a group given pla-
cebo (Placebo). The randomization code was sealed and
stored until the blind was removed.
At the time of informed consent, investigators eval-
uated the background characteristics of patients. After an
observation period of 3–14 days from the time of informed
consent, investigators assessed patients for their eligibility
for enrolment according to criteria previously described. At
the time of the eligibility assessment the UC-DAI was cal-
culated using a previously reported method.
9,10 The UC-
DAI is the sum of the mucosal appearance score (based on
the colonoscopy ﬁndings by reference to atlases of mucosal
appearance), stool frequency score, bloody stool score, and
physician’s global assessment score (stage 0, 1, 2, or 3).
Each score was based on the patients’ diary for the last
three days. The area of the inﬂammation was also deter-
mined by colonoscopy. Patients who were judged as eligi-
ble were enrolled and assigned to investigational drugs by
a central registration center, and then administration was
started. The investigational drugs were administered three
times daily for eight weeks.
During the study, each patient recorded the condition
of their bloody stools, stool frequency and drug compliance
in their diary and visited the medical center every two
weeks. Each component of UC-DAI, except the mucosal
appearance score, was assessed at each visit. Colonoscopy
was performed at eight weeks or at withdrawal from the
study, and UC-DAI was calculated at that time. To evalu-
ate safety, clinical laboratory data and vital signs were
checked at the time of informed consent and four weeks
and eight weeks after enrolment (or upon withdrawal). The
presence or absence of adverse events (AEs) and adverse
drug reactions (ADRs) were recorded by investigators at
each visit.
Statistical Analysis
In the statistical analysis, the primary endpoint was
the decrease in UC-DAI at the ﬁnal assessment. The princi-
pal aim of this study was to demonstrate two hypotheses
with closed procedure; the ﬁrst was the superiority of pH-
3.6 g over Time-2.25 g, and the second was the noninfer-
iority of pH-2.4 g to Time-2.25 g.
In the primary endpoint, a closed procedure was
adopted. Individual hypotheses were veriﬁed by the follow-
ing methods: 1) veriﬁcation of the superiority of pH-3.6 g
over Time-2.25 g: the superiority was demonstrated if the
lower limit of the 95% conﬁdence interval (CI) was more
than ‘‘0.0’’ in the difference of the decrease in UC-DAI
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1568between the groups (pH-3.6 g minus Time-2.25 g); and 2)
veriﬁcation of the noninferiority of pH-2.4 g to Time-2.25
g: the noninferiority and superiority would be demonstrated
if the lower limits of the 95% CI were more than ‘‘ 1.0’’
and ‘‘0.0’’, respectively, in the difference between the
groups (pH-2.4 g minus Time-2.25 g). The secondary end-
points were the proportion of remission and the proportion
of efﬁcacy. Remission was deﬁned as patients with a UC-
DAI of 2 or less and a bloody stool score of 0 at the ﬁnal
assessment. Efﬁcacy was deﬁned as remission or improve-
ment. Improvement was deﬁned as patients with the
decrease in UC-DAI by two points or more, except patients
who experienced a remission. In the safety endpoints the
numbers of patients with AEs and patients with ADRs
were analyzed by Fisher’s exact test.
Unless otherwise speciﬁed, differences at a ¼ 0.05
(two-sided) and P < 0.05 were considered statistically sig-
niﬁcant. Differences were considered statistically signiﬁ-
cant when the 95% CI did not include zero in the differ-
ence between two groups. Multiplicity of these analyses
was not taken into consideration. The statistical analyses
were conducted by ZERIA Pharmaceutical, Japan, based
on statistical advice of an expert independent of this study.
The number of patients required to demonstrate the
superiority of pH-3.6 g over Time-2.25 g was estimated to
be 55 at a ¼ 0.05 (two-sided) and b ¼ 0.1 when the dif-
ference between the decreases in UC-DAI of the two
groups was 2.0 and the standard deviation (SD) was 3.2.
The number of the patients required to demonstrate the
noninferiority of pH-2.4 g to Time-2.25 g was estimated to
be 54 at a ¼ 0.05 (two-sided), b ¼ 0.1 and D ¼ 1 when
the difference between the decreases in UC-DAI of the
two groups was 1.0 and the SD was 3.2. According to the
above estimations, we decided to enroll at least 60 patients
in each active-drug group considering the patients excluded
from the analysis set. Placebo was used as the reference in
the analysis for efﬁcacy, and the number of patients in the
placebo group was half of that in each of the active drug
groups.
The full analysis set (FAS) consisted of all partici-
pants except those who had not taken even one tablet of
the investigational drugs, those who did not comply with
Good Clinical Practice (GCP), those who met exclusion
criteria 1) and those whose data were missing. The per pro-
tocol set (PPS) consisted of the FAS except those who did
not fulﬁll the inclusion criteria, those who met the exclu-
sion criteria 2)–7), those who received forbidden drugs and
those whose drug compliance was less than 75%. Concern-
ing the withdrawal cases, their adoption was to be decided
before the blind was removed. The statistical analysis of
efﬁcacy was performed primarily based on data from the
FAS followed by comparison with those from the PPS. The
dataset for safety consisted of all participants except those
who had not taken even one tablet of the investigational
drug and those who did not comply with the GCP.
Independent Image Assessment Committee
We established an image assessment committee inde-
pendent from the investigators to ensure the reliability of
the mucosal appearance scores, and each of the three mem-
bers of the committee blindly and independently scored
mucosal appearance by examining photos provided by the
investigators. When the scores obtained from all three
members was the same, that score was regarded as a judg-
ment by the committee. If the scores were different, the
committe members discussed the case until they reached a
consensus. When the judgment by the committee and the
evaluation by the investigators were the same, it was
deﬁned as an agreement case.
RESULTS
Patient Demographics
Investigators obtained informed consent from 263
patients during the period from November 2005 to July
2007 and completed the ﬁnal follow-up in September 2007
(Fig. 1). Of the 263 patients, 229 patients were assigned to
all the groups (pH-2.4 g, 66; pH-3.6 g, 65; Time-2.25 g,
65; Placebo, 33). All 229 patients took the investigational
drugs at least once. Drug compliance was greater than 75%
in every patient except for 2 patients (Time-2.25 g, 1;
Placebo, 1).
A total of 47 patients (pH-2.4 g, 16; pH-3.6 g, 7;
Time-2.25 g, 14; Placebo, 10) were withdrawn from the
study. The most frequent reason for withdrawal was aggra-
vation of UC (pH-2.4 g, 9; pH-3.6 g, 1; Time-2.25 g, 7;
Placebo, 7).
There were 225 patients in the FAS (pH-2.4 g, 66;
pH-3.6 g, 64; Time-2.25 g, 63; Placebo, 32) and 222
patients in the PPS (pH-2.4 g, 65; pH-3.6 g, 62; Time-2.25
g, 63; Placebo, 32). The results were very similar when the
data were analyzed according to the FAS or PPS. There-
fore, the results analyzed according to the FAS will be
shown at the following. We did not perform adjustments
for the demographic factor because patient demographics
in all groups were similar (Table 1).
Efficacy
The decrease in UC-DAI as the primary endpoint
was most pronounced in pH-3.6 g (Table 2). The decrease
in UC-DAI was greater by 1.6 (95% CI: 0.6, 2.6) in pH-
3.6 g compared to Time-2.25 g, demonstrating the superi-
ority of pH-3.6 g over Time-2.25 g (P ¼ 0.003). The differ-
ence between pH-2.4 g and Time-2.25 g was 0.2 (95% CI:
 0.8, 1.2), demonstrating the noninferiority of pH-2.4 g to
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TABLE 1. Patient Demographics
pH-2.4 g (n ¼ 66) pH-3.6 g (n ¼ 64) Time-2.25 g (n ¼ 63) Placebo (n ¼ 32)
Sex (male/female) 38/28 36/28 37/26 16/16
Age (years)
Mean 39.4 41.6 41.2 35.8
SD 12.0 10.4 10.1 10.6
Weight (kg)
Mean 59.45 60.20 61.11 59.49
SD. 11.38 9.39 10.92 10.47
Years of disease duration
(no. of patients)
<12 1 1 69 7
<27 9 6 5
<34 4 5 2
<43 2 2 0
<54 5 3 3
 52 7 2 8 3 8 1 5
Inﬂamed areas (no. of patients)
Proctitis-type 24 24 25 11
Others 42 40 38 21
Clinical course (no. of patients)
Initial 16 14 8 5
Relapsed 50 50 55 27
UC-DAI at initial assessment
Mean 6.1 6.0 6.1 5.9
SD 1.6 1.6 1.6 1.7
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portions of the remission and efﬁcacy, were the highest in
pH-3.6 g (Fig. 2).
In the subgroup analyses, a signiﬁcant difference in
the decrease in UC-DAI was found between pH-3.6 g and
placebo in all subgroups (Table 3). Among the patients
with proctitis-type UC, there were signiﬁcant differences
both in pH-2.4 g and in pH-3.6 g as compared with pla-
cebo, but not in Time-2.25 g as compared with placebo.
Among the patients in which UC-DAI at initial assessment
was ‘‘3–5’’, the results showed a trend similar to the sub-
group of patients with proctitis-type UC. On the other
hand, among the cases where UC-DAI was ‘‘6–8’’, there
was a signiﬁcant difference only in pH-3.6 g as compared
with placebo, but not in pH-2.4 g and Time-2.25 g as com-
pared with placebo.
Reliability of the Mucosal Appearance Scores
The proportion of agreement between the judges by
the image assessment committee and the evaluations by the
investigators are summarized in Table 4. The proportion
was 67.9%, and Cohen’s j coefﬁcient was 0.497. In all the
disagreement cases there was one degree of difference in
the scores between the judges by the committee and the
evaluations by the investigators.
Safety
In patients with AEs and ADRs, there were no signif-
icant differences between each of the active drug groups
and placebo (Table 5). Serious adverse events included
aggravation of UC in 2 patients in pH-2.4 g, malaise in 1
patient in pH-3.6 g, abdominal abscess in 1 patient in pH-
3.6 g and aggravation of UC in 3 patients in Time-2.25 g.
A causal relationship to the drug could not be ruled out in
3 patients with serious AEs (1 patient in pH-2.4 g and 2
patients in Time-2.25 g).
DISCUSSION
Previous randomized controlled studies have stated
that the pH- and time-dependent release formulations of
mesalamine used in the present study were superior to pla-
cebo.
9,11 However, exposure periods and dosage differed in
the individual studies. These differences made it difﬁcult to
compare drug efﬁcacies.
TABLE 2. Decrease in the UC-DAI
pH-2.4 g (n ¼ 66) pH-3.6 g (n ¼ 64) Time-2.25 g (n ¼ 63) Placebo (n ¼ 32)
Decrease in the UC-DAI
No. of patients 58 62 60 32
Mean (95% CI ) 1.5 (0.7, 2.3) 2.9 (2.3, 3.5) 1.3 (0.6, 2.1) 0.3 ( 0.7, 1.2)
Difference from
Time-2.25 g (95% CI )
0.2 ( 0.8, 1.2) 1.6 (0.6, 2.6) — —
Difference from
Placebo (95% CI )
1.2 (0.0, 2.5) 2.7 (1.4, 3.9) 1.1 ( 0.1, 2.3) —
Decrease in the UC-DAI was calculated from the scores at the initial and ﬁnal assessments. The data of 13 patients (pH-2.4 g, 8; pH-3.6 g, 2; Time-2.25
g, 3) had to be excluded from the analysis because the mucosal appearance data were missing.
FIGURE 2. Proportion of remission and efﬁcacy. The graphs
show proportions of remission and efﬁcacy in each group
within 95% CIs. Each graph includes 225 patients for analy-
ses (pH-2.4 g, 66; pH-3.6 g, 64; Time-2.25 g, 63; Placebo, 32).
A: The proportion of patients who experienced a remission
was 30.3% (CI, 19.6–42.8) in pH-2.4 g, 45.3% (CI, 32.9–58.2)
in pH-3.6 g, 28.6% (CI, 17.9–41.3) in Time-2.25 g, and 9.4%
(CI, 2.0–25.0) in Placebo. There were statistically signiﬁcant
differences from Placebo in all active-drug groups. B: Efﬁ-
cacy was archived in 45.5% (CI, 33.2–58.1) in pH-2.4 g,
64.1% (CI, 51.1–75.6) in pH-3.6 g, 49.2% (CI, 36.4–62.1) in
Time-2.25 g, and 28.1% (CI, 13.8–46.7) in Placebo. There
were signiﬁcant differences from Placebo in both pH-3.6 g
and Time-2.25 g.
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highest efﬁcacy at every endpoint. In general, it has been
proposed that mesalamine exerts a greater therapeutic
effect at higher doses.
1,2,12 Schroeder et al
13 demonstrated
that a higher dose of the pH-dependent release formulation
of 4.8 g/day showed greater efﬁcacy than a dose of 1.6 g/












Proctitis-type No. of patients 22 23 23 11
Mean (95% CI) 1.8 (0.7, 2.8) 1.7 (0.7, 2.6) 1.1 (-0.2, 2.3)  0.4 (-1.8, 1.1)
Difference from
Time-2.25 g (95% CI)
0.7 (-0.8, 2.1) 0.6 (-0.9, 2.0) — —
Difference from
Placebo (95% CI)
2.1 (0.3, 4.0) 2.0 (0.2, 3.8) 1.5 (-0.4, 3.3) —
Others No. of patients 36 39 37 21
Mean (95% CI) 1.3 (0.2, 2.4) 3.6 (2.9, 4.4) 1.5 (0.5, 2.5) 0.6 (-0.8, 1.9)
Difference from
Time-2.25 g (95% CI)
 0.2 (-1.5, 1.2) 2.2 (0.8, 3.5) — —
Difference from
Placebo (95% CI)
0.7 (-0.9, 2.4) 3.1 (1.5, 4.7) 0.9 (-0.7, 2.5) —
UC-DAI at initial
assessment
3-5 No. of patients 23 27 24 13
Mean (95% CI) 1.7 (0.8, 2.6) 1.8 (0.9, 2.7) 1.5 (0.3, 2.6)  0.1 (-1.5, 1.3)
Difference from
Time-2.25 g (95% CI)
0.2 (-1.1, 1.6) 0.4 (-1.0, 1.7) — —
Difference from
Placebo (95% CI)
1.8 (0.1, 3.4) 1.9 (0.3, 3.5) 1.5 (-0.1, 3.2) —
6-8 No. of patients 35 35 36 19
Mean (95% CI) 1.3 (0.1, 2.5) 3.7 (2.9, 4.6) 1.2 (0.2, 2.3) 0.5 (-0.9, 1.9)
Difference from
Time-2.25 g (95% CI)
0.1 (-1.3, 1.6) 2.5 (1.1, 4.0) — —
Difference from
Placebo (95% CI)
0.9 (-0.9, 2.6) 3.3 (1.5, 5.0) 0.7 (-1.0, 2.5) —
Decrease in the UC-DAI was calculated from the scores at the initial and ﬁnal assessments. The data of 13 patients (pH-2.4 g, 8; pH-3.6 g, 2; Time-2.25
g, 3) had to be excluded from the analysis because the mucosal appearance data were missing.
TABLE 4. Agreement Between Evaluations by the Investigators and Judgments by the Image Assessment Committee
n ¼ 193
Evaluations by the Investigators
Total 012 3
Judgments by committee 0 26 9 0 0 35 Proportion of agreement (%) 67.9
1 1 16 32 30 9 7
2 0 14 41 5 60
30 0 0 1 1
Total 37 86 64 6 193 Cohen’s j coefﬁcient 0.497
Proportion of agreement (%) ¼ (number of agreement cases) / (number of cases conﬁrmed by colonoscopy) x 100
In this trial, 229 patients were allocated to an intervention. The data of 35 patients had to be excluded from the analysis because the mucosal appearance
score was missing, and the data of one patient had to be excluded from the analysis because of a GCP violation.
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1572day. In addition, when another formulation of pH-depend-
ent release mesalamine (Rowasa) was administered to
patients with active UC, UC-DAI after six weeks of treat-
ment decreased from 8.5 to 4.8 at the 4 g/day dose, from
9.0 to 7.7 at the 2 g/day dose, and from 8.2 to 7.7 in the
placebo group.
14 In this report, we also showed that the
pH-dependent release formulation at a higher dose signiﬁ-
cantly decreased UC-DAI (Table 2).
Patients with proctitis-type UC account for 40–50%
of the patients with UC.
12 Physicians often use mesalamine
suppositories and enemas to treat these patients, but com-
pliance is poorer than with oral formulations. We found
signiﬁcant differences both in the pH-2.4 g and in the pH-
3.6 g group as compared with placebo in patients with
‘‘proctitis-type’’ disease, but not in the Time-2.25 g group
(Table 3). These ﬁndings suggest that the pH-dependent
release formulation is preferable for patients with inﬂam-
mation of the distal intestine. Until now, mesalamine for-
mulations have been chosen without adequate supporting
evidence. The results of the present study provide scientiﬁc
evidence for the proper use of the different mesalamine
formulations, especially when the location of the inﬂamma-
tion is taken into consideration.
In every subgroup of disease characteristics, only the
pH-3.6 g group showed signiﬁcant differences as compared
with placebo (Table 3). Especially in subgroups classiﬁed
as ‘‘others’’ and as UC-DAI of ‘‘6–8,’’ the pH-3.6 g group
showed greater a decrease in UC-DAI compared to the
other groups. We presume that patients who are classiﬁed
as UC-DAI of ‘‘6–8’’ (i.e., the patients with more severe
disease) can only achieve an adequate level of mesalamine
at the dosage of 3.6 g/day. As a result, a substantial change
in the UC-DAI score may occur. Patients with more exten-
sive disease generally have more severe disease.
12 There-
fore, because the patients classiﬁed as ‘‘others’’ had more
severe disease than the patients with the ‘‘proctitis-type’’
UC, a substantial change in UC-DAI might be also
observed in patients classiﬁed as ‘‘others.’’
In the primary endpoint, neither the pH-2.4 g group
nor Time-2.25 g group showed signiﬁcant differences when
compared with placebo (Table 2). These results were in
contrast to the ﬁndings from previous studies.
9,11 This dis-
crepancy was likely related to the lack of power; i.e., the
number of patients in placebo was half of that in the active
drug groups because the present study was not designed
mainly for comparing the active drug groups with placebo.
The proportion of agreement between the judges by
committee and the evaluations by the investigators was
67.9% (Cohen’s j coefﬁcient: 0.497) (Table 4). Mucosal
appearance in patients with UC is often evaluated using the
Baron score,
15 which is similar to the index used in our
study. Hirai and Matsui
16 reported a proportion of agree-
ment between the scores of the two raters that used the
Baron score. In their study, the proportion of agreement
and j coefﬁcient between two raters were 51% and 0.31,
respectively, but their coefﬁcient was lower compared to
our study. In the Hirai and Matsui study, 8.7% of all
patients observed two degrees of difference in the scores
between two raters. On the other hand, in our study, there
were no cases showing two degrees of difference. Thus, we
TABLE 5. Adverse Events and Adverse Drug Reactions
pH-2.4 g (n ¼ 66) pH-3.6 g (n ¼ 64) Time-2.25 g (n ¼ 65) Placebo (n ¼ 33)
No. of Patients (%) No. of Patients (%) No. of Patients (%) No. of Patients (%)
Adverse events* 56 (84.8) 53 (82.8) 55 (84.6) 22 (66.7)
Nasopharyngitis 11 (16.7) 10 (15.6) 7 (10.8) 2 (6.1)
C-reactive protein increased 13 (19.7) 14 (21.9) 18 (27.7) 6 (18.2)
Beta-N-acetyl-D-glucosaminidase
increased
13 (19.7) 12 (18.8) 13 (20.0) 6 (18.2)
Eosinophil count increased 12 (18.2) 9 (14.1) 14 (21.5) 4 (12.1)
Lymphocyte count decreased 10 (15.2) 5 (7.8) 11 (16.9) 1 (3.0)
Blood bilirubin increased 6 (9.1) 8 (12.5) 5 (7.7) 4 (12.1)
White blood cell count
increased
4 (6.1) 4 (6.3) 7 (10.8) 2 (6.1)
Blood lactate dehydrogenase
increased
2 (3.0) 0 (0.0) 6 (9.2) 4 (12.1)
Adverse drug reactions 27 (40.9) 31 (48.4) 28 (43.1) 10 (30.3)
*Events that occurred in more than 10% of the patients in at least one group.
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gators was well controlled in our study.
In the present study, the proportion of cases showing
disagreement was  30%. This disagreement was predomi-
nately ascribed to a difference in the approach to the
patients’ mucosa, because the investigators evaluated the
actual mucous membrane through colonoscopy; whereas
the committee used photos of the mucous membrane taken
by the investigators. We provided atlases of mucosal
appearance to the investigators in order to minimize inter-
observer variation (both investigator–investigator and in-
vestigator–committee). However, as mentioned by Hirai
and Matsui,
16 further improvement in the agreement
between raters could be accomplished by better training of
the raters, the use of good photos, and so on.
Mesalamine has generally been found to be a safe
drug,
1,2 but the transfer of mesalamine from the upper gas-
trointestinal tract to the plasma should be minimized con-
sidering its nephrotoxicity. We expect the pH-dependent
release formulation to reduce the frequency of AEs because
it suppresses the transfer of mesalamine to plasma due to
its release mechanism.
3,4 However, no difference between
the two formulations in the proportion of the patients with
AEs was observed (Table 5). The wide safety margin of
mesalamine may blur the differences between the two
formulations.
In summary, this is the ﬁrst study to directly compare
the efﬁcacy and safety of two different mesalamine formu-
lations for the induction of remission in patients with UC.
The results of our study clearly showed superior efﬁcacy of
the pH-dependent release formulation administered at a
dose of 3.6 g/day and superior characteristics of this formu-
lation to treat patients with proctitis-type UC. However, it
is unknown whether the formulation is also efﬁcacious in
patients with more severe UC because the subjects in this
study were patients with mild-to-moderate active UC.
Mesalamine is considered safer than corticosteroids.
Accordingly, further research will be necessary to fully
evaluate the role of mesalamine formulations for the treat-
ment of severe UC. If this is accomplished, it is likely that
mesalamine contributes to the improvement in the quality
of life of patients with UC.
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